HC Wainwright reissued their buy rating on shares of Protalix BioTherapeutics (NYSE:PLX – Free Report) in a research note published on Wednesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ FY2026 earnings at $0.29 EPS, Q4 2027 earnings at $0.06 EPS and FY2027 earnings at $0.11 EPS.
Protalix BioTherapeutics Price Performance
Shares of PLX stock opened at $2.64 on Wednesday. The stock has a market capitalization of $212.71 million, a price-to-earnings ratio of -20.31 and a beta of 0.02. The company’s fifty day simple moving average is $2.44 and its two-hundred day simple moving average is $2.33. Protalix BioTherapeutics has a 1 year low of $1.60 and a 1 year high of $3.19.
Institutional Trading of Protalix BioTherapeutics
A number of institutional investors have recently added to or reduced their stakes in PLX. Equitable Holdings Inc. purchased a new position in Protalix BioTherapeutics during the 2nd quarter valued at about $31,000. Ieq Capital LLC bought a new stake in shares of Protalix BioTherapeutics during the second quarter valued at about $32,000. Bank of America Corp DE lifted its holdings in shares of Protalix BioTherapeutics by 364,766.7% in the second quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock worth $32,000 after buying an additional 21,886 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Protalix BioTherapeutics by 126.5% in the third quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after buying an additional 8,498 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Protalix BioTherapeutics in the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.
About Protalix BioTherapeutics
Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.
The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.
Featured Stories
- Five stocks we like better than Protalix BioTherapeutics
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
